In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy

In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy

Background CMP-001 is a novel Toll-like receptor-9 agonist that consists of an unmethylated CpG-A motif-rich G10 oligodeoxynucleotide (ODN) encapsulated in virus-like particles. In situ vaccination of CMP-001 is believed to activate local tumor-associated plasmacytoid dendritic cells (pDCs) leading...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhaoming Wang, George J Weiner, Yinwen Cheng, Caitlin D Lemke-Miltner, Wattawan Wongpattaraworakul, Carlos H F Chan, Aliasger K Salem, Andrean L Simons
Format: Article
Language:English
Published: BMJ Publishing Group 2020-10-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e000940.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items